CN112839959A - 用于纯化异源二聚多特异性抗体的方法 - Google Patents

用于纯化异源二聚多特异性抗体的方法 Download PDF

Info

Publication number
CN112839959A
CN112839959A CN201980066235.1A CN201980066235A CN112839959A CN 112839959 A CN112839959 A CN 112839959A CN 201980066235 A CN201980066235 A CN 201980066235A CN 112839959 A CN112839959 A CN 112839959A
Authority
CN
China
Prior art keywords
antibody
elution buffer
multispecific
binding
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980066235.1A
Other languages
English (en)
Chinese (zh)
Inventor
B·约根森
U·谢伦伯格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TeneoBio Inc
Original Assignee
TeneoBio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TeneoBio Inc filed Critical TeneoBio Inc
Publication of CN112839959A publication Critical patent/CN112839959A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G or L chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201980066235.1A 2018-09-21 2019-09-20 用于纯化异源二聚多特异性抗体的方法 Pending CN112839959A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862734566P 2018-09-21 2018-09-21
US62/734,566 2018-09-21
US201862742821P 2018-10-08 2018-10-08
US62/742,821 2018-10-08
PCT/US2019/052199 WO2020061478A2 (en) 2018-09-21 2019-09-20 Methods for purifying heterodimeric, multispecific antibodies

Publications (1)

Publication Number Publication Date
CN112839959A true CN112839959A (zh) 2021-05-25

Family

ID=68240802

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980066235.1A Pending CN112839959A (zh) 2018-09-21 2019-09-20 用于纯化异源二聚多特异性抗体的方法

Country Status (11)

Country Link
US (2) US20210355215A1 (https=)
EP (1) EP3853253A2 (https=)
JP (2) JP2022501357A (https=)
KR (1) KR20210063354A (https=)
CN (1) CN112839959A (https=)
BR (1) BR112021004680A2 (https=)
CA (1) CA3113057A1 (https=)
IL (1) IL281570A (https=)
MX (1) MX2021003169A (https=)
SG (1) SG11202102713TA (https=)
WO (1) WO2020061478A2 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3029209A1 (en) 2016-06-21 2017-12-28 Teneobio, Inc. Cd3 binding antibodies
IL264941B2 (en) 2016-08-24 2025-12-01 Teneobio Inc Transgenic non-human animals producing modified heavy chain-only antibodies
FI4050034T3 (fi) * 2016-09-14 2024-06-10 Teneoone Inc Cd3:een sitoutuvia vasta-aineita
NZ754713A (en) 2016-12-21 2025-11-28 Teneobio Inc Anti-bcma heavy chain-only antibodies
US11427642B2 (en) 2017-06-20 2022-08-30 Teneoone, Inc. Anti-BCMA heavy chain-only antibodies
WO2019126756A1 (en) 2017-12-22 2019-06-27 Teneobio, Inc. Heavy chain antibodies binding to cd22
JP7776987B2 (ja) 2019-04-05 2025-11-27 テネオバイオ， インコーポレイテッド Ｐｓｍａに結合する重鎖抗体
CN114206927B (zh) 2019-06-14 2025-03-21 特尼奥生物股份有限公司 与cd22和cd3结合的多特异性重链抗体
KR102153258B1 (ko) * 2020-02-21 2020-09-07 프레스티지바이오로직스 주식회사 베바시주맙 정제의 최적화된 방법
TWI838621B (zh) * 2020-04-29 2024-04-11 美商泰尼歐萬公司 具有經修飾重鏈恆定區之多特異性重鏈抗體
AU2021263448B2 (en) * 2020-04-29 2026-02-05 Teneobio, Inc. Multispecific heavy chain antibodies with modified heavy chain constant regions
KR102744698B1 (ko) * 2020-04-29 2024-12-24 테네오원, 인코포레이티드 변형된 중쇄 불변 영역을 갖는 다중특이적 중쇄 항체
CN114539417A (zh) * 2020-11-26 2022-05-27 盛禾(中国)生物制药有限公司 一种有效去除双特异性抗体同源二聚体的层析纯化工艺
WO2022222949A1 (zh) * 2021-04-23 2022-10-27 和铂医药(上海)有限责任公司 一种双特异性抗体的纯化方法
WO2025251034A1 (en) * 2024-05-31 2025-12-04 Amgen Inc. Purification method

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19836213A1 (de) * 1998-08-11 2000-02-24 Gerhard Harry Scholz Verfahren zur Elution von Biomolekülen von Chromatographie-Materialien
AU2001270609A1 (en) * 2000-06-30 2002-01-14 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Heterodimeric fusion proteins
US20140056897A1 (en) * 2011-03-10 2014-02-27 Hco Antibody, Inc. Bispecific three-chain antibody-like molecules
EP2825559A2 (en) * 2012-03-13 2015-01-21 Novimmune SA Readily isolated bispecific antibodies with native immunoglobulin format
WO2015033223A2 (en) * 2013-09-03 2015-03-12 Novimmune S.A. Readily isolated bispecific binding molecules with native format having mutated constant regions
US20160024147A1 (en) * 2014-07-26 2016-01-28 Regeneron Pharmaceuticals, Inc. Purification Platform for Bispecific Antibodies
CN107446044A (zh) * 2016-05-30 2017-12-08 上海迈泰君奥生物技术有限公司 一种纯化抗体的方法及所用缓冲液
WO2018018011A2 (en) * 2016-07-22 2018-01-25 Amgen Inc. Methods of purifying fc-containing proteins
US20180079797A1 (en) * 2015-04-10 2018-03-22 Adimab, Llc Methods for purifying heterodimeric multispecific antibodies from parental homodimeric antibody species
US20180179285A1 (en) * 2014-05-16 2018-06-28 Pfizer Inc. Bispecific antibodies
WO2019183406A1 (en) * 2018-03-21 2019-09-26 Invenra Inc. Multispecific antibody purification with ch1 resin

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
AU632065B2 (en) 1988-09-23 1992-12-17 Novartis Vaccines And Diagnostics, Inc. Cell culture medium for enhanced cell growth, culture longevity and product expression
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
WO2004042017A2 (en) 2002-10-31 2004-05-21 Genentech, Inc. Methods and compositions for increasing antibody production
CA2513113A1 (en) 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
US20080286819A1 (en) 2005-11-07 2008-11-20 Ravetch Jeffrey V Reagents, Methods and Systems for Selecting a Cytotoxic Antibody or Variant Thereof
MX2008012843A (es) 2006-04-05 2009-01-19 Univ Rockefeller Polipeptidos con propiedades antiinflamatorias aumentadas y citotoxicas reducidas y metodos relacionados.
LT3660032T (lt) * 2009-06-25 2026-02-25 Amgen Inc. Ne žinduolių sistemoje ekspresuotų baltymų surišamojo gryninimo būdai
NZ754713A (en) 2016-12-21 2025-11-28 Teneobio Inc Anti-bcma heavy chain-only antibodies

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19836213A1 (de) * 1998-08-11 2000-02-24 Gerhard Harry Scholz Verfahren zur Elution von Biomolekülen von Chromatographie-Materialien
AU2001270609A1 (en) * 2000-06-30 2002-01-14 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Heterodimeric fusion proteins
US20140056897A1 (en) * 2011-03-10 2014-02-27 Hco Antibody, Inc. Bispecific three-chain antibody-like molecules
EP2825559A2 (en) * 2012-03-13 2015-01-21 Novimmune SA Readily isolated bispecific antibodies with native immunoglobulin format
WO2015033223A2 (en) * 2013-09-03 2015-03-12 Novimmune S.A. Readily isolated bispecific binding molecules with native format having mutated constant regions
US20150094451A1 (en) * 2013-09-03 2015-04-02 Novimmune S.A. Readily Isolated Bispecific Binding Molecules with Native Format Having Mutated Constant Regions
US20180179285A1 (en) * 2014-05-16 2018-06-28 Pfizer Inc. Bispecific antibodies
US20160024147A1 (en) * 2014-07-26 2016-01-28 Regeneron Pharmaceuticals, Inc. Purification Platform for Bispecific Antibodies
US20180079797A1 (en) * 2015-04-10 2018-03-22 Adimab, Llc Methods for purifying heterodimeric multispecific antibodies from parental homodimeric antibody species
CN108472360A (zh) * 2015-04-10 2018-08-31 阿迪马布有限责任公司 从亲代同源二聚抗体种类中纯化异源二聚多特异性抗体的方法
CN107446044A (zh) * 2016-05-30 2017-12-08 上海迈泰君奥生物技术有限公司 一种纯化抗体的方法及所用缓冲液
WO2018018011A2 (en) * 2016-07-22 2018-01-25 Amgen Inc. Methods of purifying fc-containing proteins
WO2019183406A1 (en) * 2018-03-21 2019-09-26 Invenra Inc. Multispecific antibody purification with ch1 resin

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
EDMUND A. ROSSI ET AL.: "Pretargeting of carcinoeembryonic antigen-expressing cancers with a trivalent bispecific fusion protein produced in myeloma cells", 《PRETARGETING STUDIES》, vol. 11, no. 19, 1 October 2005 (2005-10-01), pages 7122 - 7129 *
JENNIFER BRATT ET AL.: "Therapeutic lg G-like bispecific antibodies :modular versatility and manufacturing challengers", 《2017BIOPROCESS INTERNATIONAL》, vol. 15, no. 11, 16 February 2018 (2018-02-16), pages 1 - 14, XP055562245 *
STARLYNN C. CLARKE ET AL.: "multispecific antiboday development platform based on human heavy chain antibodies", 《FRONTIERS IN IMMUNOLOGY》, vol. 9, 7 January 2019 (2019-01-07), pages 1 - 13 *
YANLI WANG ET AL.: "Application of enhanced electronegative multimodal chromatography as the primary capture step for immunoglobulin G purifcation", 《AMB EXPRESS》, vol. 93, no. 8, 31 August 2018 (2018-08-31), pages 1 - 7 *
吴梧桐主编: "《生物制药工艺学》", 31 August 2015, 中国医药科技出版社, pages: 541 *
杨玉丹: "新型抗CD133xCD3双特异性抗体治疗晚期结直肠癌的基础研究", 《中国博士学位论文全文数据库 医药卫生科技辑》, no. 2017, 15 August 2017 (2017-08-15), pages 072 - 175 *

Also Published As

Publication number Publication date
EP3853253A2 (en) 2021-07-28
WO2020061478A3 (en) 2020-04-30
BR112021004680A2 (pt) 2021-08-31
KR20210063354A (ko) 2021-06-01
JP2022501357A (ja) 2022-01-06
JP2024099610A (ja) 2024-07-25
AU2019343053A1 (en) 2021-04-15
IL281570A (en) 2021-05-31
MX2021003169A (es) 2021-08-11
US20250197497A1 (en) 2025-06-19
WO2020061478A2 (en) 2020-03-26
CA3113057A1 (en) 2020-03-26
US20210355215A1 (en) 2021-11-18
SG11202102713TA (en) 2021-04-29

Similar Documents

Publication Publication Date Title
US20250197497A1 (en) Methods for purifying heterodimeric, multispecific antibodies
JP2022501357A5 (https=)
US10363496B2 (en) Method for purification of monoclonal antibodies
CA2899308C (en) Low acidic species adalimumab compositions and uses thereof
CN102712673B (zh) 用于纯化含fc的蛋白的色谱方法
KR102618831B1 (ko) 양이온 교환 크로마토그래피 세척 완충액
JP2010516651A (ja) Ｆｃ含有タンパク質の精製のための方法
CN1810292A (zh) 用离子交换层析纯化蛋白质
RS57013B1 (sr) Korektno savijeni etanercept sa visokom čistoćom i odličnim prinosom
MX2009002014A (es) Proceso para la purificacion de proteinas que contienen fc.
TW201348247A (zh) 利用蛋白質ａ親和性層析之非人類抗體之新穎純化
JPWO2020061478A5 (https=)
KR20190043601A (ko) 항체를 정제하는 방법
JP2011500757A (ja) Ｆｃ含有タンパク質の精製方法
JP2025528213A (ja) 複数ドメイン結合性分子
JP2017507132A (ja) 抗体プロセス
AU2019343053B2 (en) Methods for purifying heterodimeric, multispecific antibodies
JP2010501622A (ja) Ｆｃ−融合タンパク質の精製法
RU2820588C2 (ru) Способы очистки гетеродимерных полиспецифических антител
US20240383945A1 (en) Purification method of antibody composition
JP2016503062A (ja) 免疫複合体の製造方法
WO2025219869A1 (en) Methods of purifying immunoglobulins comprising n-terminal glutamine

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination